Latest News
Einhorn's DME Capital Takes Stake in StubHub, World Cup Demand Lifts Stock
StubHub shares jumped 23% after David Einhorn's DME Capital disclosed a new stake. Guggenheim reiterated its Buy rating, pointing to World Cup ticket demand and strong Q1 earnings.
Markets Rally on Iran Deal Hopes; Mortgage Rates Slip, Tech Stocks Surge
US stock futures rallied Tuesday amid easing geopolitical tensions and lower oil prices. Mortgage rates hit a one-month low, while SoFi and Grab shares climbed. Rathbones Group tumbled after regulatory action.
Intel Gains as Chip Stocks Rally on Easing Inflation, AI Optimism
Intel shares rose $3.26 to $127.86 as chip stocks rallied on easing inflation and AI optimism. The Philadelphia Semiconductor Index closed at a new high. Investors now await Intel's Q2 earnings on July 23 for proof of demand-driven revenue growth.
Dave & Buster's Shares Plunge After Q1 Miss, Comps Slide 5.4%
Dave & Buster's shares fell 4.72% and dropped further after hours as Q1 revenue, adjusted profit, and comparable-store sales all missed expectations.
HUBC Stock Skyrockets on Filing Activity and Nasdaq Compliance Concerns
HUBC shares jumped 42% following ownership filings and a reverse split, but the real focus is on the overdue 2025 Form 20-F and Nasdaq compliance plan due July 17.
Nvidia's $25B Bond Sale Fuels Share Rally as AI Demand Stays Strong
Nvidia shares jumped 3.5% after a $25 billion bond sale, upsized from $20 billion due to $85 billion investor demand, signaling strong credit confidence ahead of August 26 earnings.
Nokia Shares Retreat as AI-Driven Rally Pauses Ahead of Q2 Report
Nokia shares dropped 3.32% in Helsinki as the AI trade cools, with investors awaiting July 23 Q2 results to validate a 74% three-month rally.
American Airlines Stock Rises on Oil Price Drop Amid Iran Deal
American Airlines shares climbed 3.3% to $15.46 after oil prices plunged on a U.S.-Iran deal easing Strait of Hormuz fears, lifting hopes for lower fuel costs.
Intellia Therapeutics Surges 23% on Promising Phase 3 Data for CRISPR Therapy
Intellia Therapeutics shares surged 23% to $14.92 after Phase 3 data showed lonvo-z reduced hereditary angioedema attacks by up to 91% versus placebo, with FDA filing as the next catalyst.
Keel Infrastructure Rises as ATB Reaffirms Bullish Stance Post $458M Financing
KEEL closed at $5.66, up 1.25%, after ATB Capital Markets resumed coverage with an Outperform rating and $10 target, citing the company's $458 million convertible-note financing for AI and HPC data-center growth.
POET Technologies Surges on AI Photonics Hype, Financials Show Big Gap
POET Technologies rose to $13.93 on heavy volume, driven by AI photonics hopes, but with minimal revenue and a net loss, its $2.4 billion valuation remains speculative.